New Therapeutics for Hepatitis B: The Road to Cure.

Journal Article (Journal Article;Review)

Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable treatment response, necessitating indefinite treatment in the majority of cases, have resulted in low uptake of testing and treatment, particularly in regions where comprehensive primary care is lacking and access to affordable testing and treatment is limited. Multiple targeted therapies are now in early human study with the primary goal to achieve persistent HBV DNA and hepatitis B surface antigen suppression after a finite course of treatment, which is referred to as functional cure. This article summarizes the current therapies for HBV infection and discusses the limitations of these therapies, novel approaches to HBV cure, and therapeutic endpoints of clinical trials aimed to cure hepatitis B.

Full Text

Duke Authors

Cited Authors

  • Naggie, S; Lok, AS

Published Date

  • January 27, 2021

Published In

Volume / Issue

  • 72 /

Start / End Page

  • 93 - 105

PubMed ID

  • 33085923

Electronic International Standard Serial Number (EISSN)

  • 1545-326X

Digital Object Identifier (DOI)

  • 10.1146/annurev-med-080119-103356


  • eng

Conference Location

  • United States